Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 19, 2013, Pages 7536-7551

  Ferlin, Maria Grazia ^a   Carta, Davide ^a   Bortolozzi, Roberta ^a   Ghodsi, Razieh ^b   Chimento, Adele ^c   Pezzi, Vincenzo ^c   Moro, Stefano ^a   Hanke, Nina ^d   Hartmann, Rolf W ^e   Basso, Giuseppe ^a   Viola, Giampietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF CALABRIA   (Italy)

^d SAARLAND UNIVERSITY   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(2 METHYL 7H PYRROLO[2,3 H]QUINOLIN 4 YL)METHANOL; (2 PHENYL 7H PYRROLO[2,3 H]QUINOLIN 4 YL)METHANOL; (3 ETHYL 7 PHENYL 3H PYRROLO[3,2 F]QUINOLIN 9 YL)METHANOL; (7 ETHYL 2 PHENYL 7H PYRROLO[2,3 H]QUINOLIN 4 YL)METHANOL; 2 (4 METHOXYPHENYL) 7H PYRROLO[2,3 H]QUINOLINE 4 CARBOXYLIC ACID; 2 METHYL 7H PYRROLO[2,3 H]QUINOLINE 4 CARBOXYLIC ACID; 2 PHENYL 7H PYRROLO[2,3 H]QUINOLINE 4 CARBOXYLIC ACID; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 2 (4 METHOXYPHENYL) 7H PYRROLO[2,3 H]QUINOLINE; 4 [(1H IMIDAZOL 1 YL)METHYL] 2 (4 METHOXYPHENYL) 7H PYRROLO[2,3 H]QUINOLINE; 4 [(1H IMIDAZOL 1 YL)METHYL] 2 METHYL 7H PYRROLO[2,3 H]QUINOLINE; 4 [(1H IMIDAZOL 1 YL)METHYL] 2 PHENYL 7H PYRROLO[2,3 H]QUINOLINE; 4 [(1H IMIDAZOL 1 YL)METHYL] 7 ETHYL 2 PHENYL 7H PYRROLO[2,3 H]QUINOLINE; 9 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 3 ETHYL 7 PHENYL 3H PYRROLO[2,3 H]QUINOLINE; 9 [(1H IMIDAZOL 1 YL)METHYL] 3 ETHYL 7 PHENYL 3H PYRROLO[3,2 F]QUINOLINE; [2 (4 METHOXYPHENYL) 7H PYRROLO[2,3 H]QUINOLIN 4 YL]METHANOL; AROMATASE INHIBITOR; AZOLYLMETHYLPYRROLOQUINOLINE DERIVATIVE; CYTOCHROME P450 17; ETHYL 2 METHYL 7H PYRROLO[2,3 H]QUINOLINE 4 CARBOXYLIC ACID; ETHYL 3 ETHYL 7 PHENYL 3H PYRROLO[3,2 F]QUINOLINE 9 CARBOXYLIC ACID; ETHYL 7 ETHYL 2 PHENYL 7H PYRROLO[2,3 H]QUINOLINE 4 CARBOXYLIC ACID; HEME; LETROZOLE; QUINOLINE DERIVATIVE; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE ARREST; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; FLOW CYTOMETRY; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING; MOLECULAR LIBRARY; NUCLEAR OVERHAUSER EFFECT; PHYSICAL CHEMISTRY; PREDICTIVE VALUE; PROTON NUCLEAR MAGNETIC RESONANCE; SIMULATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; AZOLES; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CRICETINAE; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGENS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PYRROLES; QUINOLINES; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885631853     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400377z     Document Type: Article

References (43)

1. Spicer, J.; Ellis, P. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition Cancer Lett. 2007, 248, 165-174
2. Santen, R. J.; Brodie, H.; Simpson, E. R.; Siiteri, P. K.; Brodie, A. History of aromatase: saga of an important biological mediator and therapeutic target Endocr. Rev. 2009, 30, 343-375
3. Hartmann, R. W.; Batzl, C.; Pongratz, T. M.; Mannschreck, A. Synthesis and aromatase inhibition of 3-cycloalkyl-substituted 3-(4- aminophenyl) piperidine-2,6-diones J. Med. Chem. 1992, 35, 2210-2214
4. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones J. Med. Chem. 1986, 29, 1362-1369
5. Park, W. C.; Jordan, V. C. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention Trends Mol. Med. 2002, 8, 82-88
6. Jordan, V. C. Tamoxifen: toxicity and drug resistance during the treatment and prevention of breast cancer Annu. Rev. Pharmacol. Toxicol. 1995, 35, 195-211
7. Macedo, L. F.; Sabnis, G.; Brodie, A. Aromatase inhibitors and breast cancer Ann. N.Y. Acad. Sci. 2009, 1155, 162-173
8. Chumsri, S.; Howes, T.; Bao, T.; Sabnis, G.; Brodie, A. Aromatase, aromatase inhibitors, and breast cancer J. Steroid Biochem. Mol. Biol. 2011, 125, 13-22
9. Sestak, I.; Cuzick, J.; Sapunar, F.; Eastell, R.; Forbes, J. F.; Bianco, A. R.; Buzdar, A. U. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis Lancet Oncol. 2008, 9, 866-872
10. Wong, Z. W.; Ellis, M. J. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br. J. Cancer 2004, 90, 20-25
11. Goss, P. E.; Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer J. Clin. Oncol. 2001, 19, 881-894
12. Miller, W. R.; Larionov, A. A. Understanding the mechanisms of aromatase inhibitor resistance Breast Cancer Res. 2012, 14, 201
13. Cavazzoni, A.; Bonelli, M. A.; Fumarola, C.; La Monica, S.; Airoud, K.; Bertoni, R.; Alfieri, R. R.; Galetti, M.; Tramonti, S.; Galvani, E.; Harris, A. L.; Martin, L. A.; Andreis, D.; Bottini, A.; Generali, D.; Petronini, P. G. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones Cancer Lett. 2012, 323, 77-87
14. Yin, L.; Hu, Q.; Hartmann, R. W. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks J. Med. Chem. 2013, 56, 460-470
15. Hu, Q.; Yin, L.; Hartmann, R. W. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer J. Med. Chem. 2012, 55, 7080-7089
16. Ferlin, M. G.; Chiarelotto, G.; Gasparotto, V.; Dalla Via, L.; Pezzi, V.; Barzon, L.; Palu, G.; Castagliuolo, I. Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones J. Med. Chem. 2005, 48, 3417-3427
17. Campbell, D. R.; Kurzer, M. S. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes J. Steroid Biochem. Mol. Biol. 1993, 46, 381-388
18. Kellis, J. T., Jr.; Vickery, L. E. Inhibition of human estrogen synthetase (aromatase) by flavones Science 1984, 225, 1032-1034
19. Hodek, P.; Trefil, P.; Stiborová, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450 Chem.-Biol. Interact. 2002, 139, 1-21
20. Pouget, C.; Yahiaoui, S.; Fagnere, C.; Habrioux, G.; Chulia, A. J. Synthesis and biological evaluation of 4-imidazolylflavans as nonsteroidal aromatase inhibitors Bioorg. Chem. 2004, 32, 494-503
21. Stefanachi, A.; Favia, A. D.; Nicolotti, O.; Leonetti, F.; Pisani, L.; Catto, M.; Zimmer, C.; Hartmann, R. W.; Carotti, A. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase J. Med. Chem. 2011, 54, 1613-1625
22. Lézé, M. -.; Palusczak, A.; Hartmann, R. W.; Le Borgne, M. Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4713-4715
23. Gobbi, S.; Zimmer, C.; Belluti, F.; Rampa, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation J. Med. Chem. 2010, 53, 5347-5351
24. Doiron, J.; Soultan, A. H.; Richard, R.; Touré, M. M.; Picot, N.; Richard, R.; Čuperlović-Culf, M.; Robichaud, G. A.; Touaibia, M. Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3- triazole letrozole-based analogues as aromatase inhibitors Eur. J. Med. Chem. 2011, 46, 4010-4024
25. Doebner, O.; v. Miller, W. Ueber eine dem chinolin homologe base Ber. Dtsch. Chem. Ges. 1881, 14, 2812-2817
26. Gasparotto, V.; Castagliuolo, I.; Ferlin, M. G. 3-Substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines J. Med. Chem. 2007, 50, 5509-5513
27. Zarghi, A.; Ghodsi, R. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors Bioorg. Med. Chem. 2010, 18, 5855-5860
28. Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Hu, Q.; Hille, U. E.; Jagusch, C.; Jahn-Hoffmann, K.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Hartmann, R. W. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: Synthesis, biological evaluation and molecular modelling Arch. Pharm. (Weinheim, Ger.) 2008, 341, 547-609
29. Lephart, E. D.; Simpson, E. R. Assay of aromatase activity Methods Enzymol. 1991, 206, 477-483
30. Montanaro, D.; Maggiolini, M.; Recchia, A. G.; Sirianni, R.; Aquila, S.; Barzon, L.; Fallo, F.; Andò, S.; Pezzi, V. Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation J. Mol. Endocrinol. 2005, 35, 245-256
31. Catalano, S.; Barone, I.; Giordano, C.; Rizza, P.; Qi, H.; Gu, G.; Malivindi, R.; Bonofiglio, D.; Andò, S. Rapid estradiol/ERα signaling enhances aromatase enzymatic activity in breast cancer cells Mol. Endocrinol. 2009, 23, 1634-1645
32. Ferlin, M. G.; Bortolozzi, R.; Brun, P.; Castagliuolo, I.; Hamel, E.; Basso, G.; Viola, G. Synthesis and in vitro evaluation of 3 H -pyrrolo[3,2- f ]quinolin-9-one derivatives that show potent and selective antileukemic activity ChemMedChem 2010, 5, 1373-1385
33. Azria, D.; Larbouret, C.; Cunat, S.; Ozsahin, M.; Gourgou, S.; Martineau, P.; Evans, D. B.; Romieu, G.; Pujol, P.; Pèlegrin, A. Letrozole sensitizes breast cancer cells to ionizing radiation Breast Cancer Res. 2005, 7, R156-R163
34. Akli, S.; Bui, T.; Wingate, H.; Biernacka, A.; Moulder, S.; Tucker, S. L.; Hunt, K. K.; Keyomarsi, K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors Clin. Cancer Res. 2010, 16, 1179-1190
35. Ghosh, D.; Griswold, J.; Erman, M.; Pangborn, W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase Nature 2009, 457, 219-223
36. Recanatini, M.; Cavalli, A.; Valenti, P. Nonsteroidal aromatase inhibitors: recent advances Med. Res. Rev. 2002, 22, 282-304
37. Stardrop, version 5.3; Optibrium Ltd. (7221 Cambridge Research Park, Beach Drive, Cambridge CB25 9TL, U.K.).
38. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells Endocr. Res. 1995, 21, 443-448
39. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17a-hydroxylase-C17,20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63
40. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179
41. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32
42. MOE (Molecular Operating Environment), version 2011.10; Chemical Computing Group Inc. (1010 Sherbooke Street West, Suite No. 910, Montreal, Quebec, Canada), 2010.
43. GOLD Suite, version 5.1; Cambridge Crystallographic Data Centre: Cambridge, U.K.